Caribou Biosciences CMO Syed Rizvi to leave Dec 31, 2023; severance terms set

Caribou Biosciences, Inc.

Dr. Rizvi's departure effective Dec 31, 2023; previously announced Dec 12, 2023.
Separation agreement provides 9 months base salary and COBRA premium reimbursement.
15,000 RSUs will vest on Jan 18, 2024 as originally scheduled.
Post-termination exercise period for vested options extended through June 30, 2024.
No successor named; bonus for 2023 at board discretion.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Syed Rizvi

Chief Medical Officer

CRBU · Caribou Biosciences, Inc.

Effective: 2023-12-31
Filed: December 22, 2023, 6:59 PM ET

As previously announced on December 12, 2023, Syed Rizvi, M.D., the Chief Medical Officer of Caribou Biosciences, Inc. (the “Company”), will be leaving the Company effective December 31, 2023.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Syed Rizvi departed as Chief Medical Officer at Caribou Biosciences, Inc..

Action: leaving
Role: Chief Medical Officer

Exact text from the filing

As previously announced on December 12, 2023, Syed Rizvi, M.D., the Chief Medical Officer of Caribou Biosciences, Inc. (the “Company”), will be leaving the Company effective December 31, 2023.

View on SEC.gov

Caribou Biosciences, Inc. filing history →

Source: SEC EDGAR

accession 0001619856-23-000138

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.